INSIGHT REPORT CALENDAR

NEWSLETTER

Like this article?

Sign up to our free newsletter

Gide advises Furui on investment in Median Technologies

Gide is advising Inner Mongolia Furui Medical Science, a Chinese company dedicated to pharmaceutical, diagnosis and medical services, on its investment in Median Technologies.

Median specialises in medical imaging software and services dedicated to oncology clinical trials, cancer screening and clinical practice. 
 
The transaction, which is subject to customary conditions, will consist in a capital increase of Median Technologies at a price of EUR13 per share, representing a total amount of EUR19,599,996 reserved to Furui Medical Science Company Luxembourg, a wholly owned subsidiary of Furui.
 
The completion of the transaction will allow Furui Medical Science Company Luxembourg to hold 13.01 per cent of the share capital and 13.03 per cent of the voting rights of Median Technologies.
 
The Gide team advising Furui on this transaction comprises Antoine Tézenas du Montcel (partner), Régis Henry and Elise Bernard in Paris and Ronan Diot (counsel) in Beijing.
 
Median Technologies was advised by Roy Arakelian (partner), Madia Iliopoulou, Clémentine Kervran and Olivier Chapalain from PDGB Avocats.  

Like this article? Sign up to our free newsletter

FEATURED

Tech Stocks

MOST RECENT

FURTHER READING